{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T02:02:39Z","timestamp":1784426559272,"version":"3.55.0"},"reference-count":17,"publisher":"Innovative Healthcare Institute","issue":"3","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pembrolizumab-based neoadjuvant chemoimmunotherapy following the KEYNOTE-522 regimen (NCT03036488) is a standard treatment approach for stage II and III triple-negative breast cancer (TNBC). Real-world evidence on the impact of germline BRCA status on pathologic complete response (pCR) and survival outcomes remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective single-center cohort study of patients with stage II\u2013III TNBC treated with a KEYNOTE-522 regimen between January 2021 and December 2023. Only patients with documented germline BRCA status were included. The primary end point was pCR rate, defined as achievement of ypT0\/is ypN0. Secondary end points included treatment delivery (completion and early discontinuation), postneoadjuvant systemic therapy patterns, recurrence-free survival (RFS), and overall survival (OS). Categorical variables were compared using Fisher\u2019s exact test, and survival outcomes were estimated using Kaplan-Meier methods and compared with log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1004 patients with breast cancer screened between 2021 and 2023, 125 had TNBC. After exclusion of patients who did not receive a KEYNOTE-522 regimen, had metastatic disease, underwent definitive surgery before neoadjuvant systemic therapy, had unretrievable BRCA status, or had other missing key eligibility data, 54 patients were eligible for analysis. The final cohort included 11 patients who were BRCA+ and 43 who were BRCA\u2212. The BRCA+ patients were younger than BRCA\u2212 patients (median 38 vs 46 years;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018). pCR was evaluable in 52 patients and was achieved in 31 of 52 patients (60%) overall; pCR was numerically higher in BRCA+ vs BRCA\u2212 patients (73% [8 of 11] vs 56% [23 of 41];\n                      <jats:italic>p<\/jats:italic>\n                      = 0.49). Median follow-up was 25 months. Two-year RFS was 100% in BRCA+ and 75.4% in BRCA\u2212 patients (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      = 0.068), whereas 2-year OS was 100% and 88%, respectively (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      = 0.272). Within the BRCA+ subgroup, the prognostic significance of pCR could not be assessed because no recurrence or death events were observed during follow-up. Within the BRCA\u2212 subgroup, pCR strongly stratified prognosis, with 2-year RFS of 100% in patients achieving pCR vs 45.5% in those without pCR (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      = 0.00004), and 2-year OS of 100% vs 72.7%, respectively (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Germline\n                      <jats:italic>BRCA<\/jats:italic>\n                      positivity was associated with a numerically higher pCR rate, but differences in pCR and survival by BRCA status were not statistically significant. Given the limited sample size and low event counts, these findings should be considered hypothesis-generating. Recurrence events clustered in BRCA\u2212 patients and were driven predominantly by those without pCR, supporting further study of optimized postneoadjuvant escalation strategies for residual BRCA\u2212 disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-26-11","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:42:40Z","timestamp":1784425360000},"page":"113-119","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study"],"prefix":"10.36401","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-3995","authenticated-orcid":true,"given":"Mohammad","family":"Aldawoud","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5414-7532","authenticated-orcid":true,"given":"Fatima","family":"Faqihi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najd","family":"Algazlan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almazyad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Altamimi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojahed","family":"Rudaini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alwohaibi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besher","family":"Alghazi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alturki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatoon","family":"Bakhribah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-4906","authenticated-orcid":true,"given":"Abdullah","family":"Altwairgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-9-3-113-b01","series-title":"Lancet","first-page":"164","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","unstructured":"Cortazar P,Zhang L,Untch M, et al.. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u2013172. DOI: 10.1016\/S0140-6736(13)62422-8"},{"key":"i2590-017X-9-3-113-b02","series-title":"N Engl J Med","first-page":"810","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","unstructured":"Schmid P,Cortes J,Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u2013821. DOI: 10.1056\/NEJMoa1910549"},{"key":"i2590-017X-9-3-113-b03","series-title":"N Engl J Med","first-page":"556","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","unstructured":"Schmid P,Cortes J,Dent R, et al.. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556\u2013567. DOI: 10.1056\/NEJMoa2112651"},{"key":"i2590-017X-9-3-113-b04","series-title":"N Engl J Med","first-page":"2394","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","unstructured":"Tutt ANJ,Garber JE,Kaufman B, et al.. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u20132405. DOI: 10.1056\/NEJMoa2105215"},{"key":"i2590-017X-9-3-113-b05","series-title":"N Engl J Med","first-page":"2147","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","unstructured":"Masuda N,Lee SJ,Ohtani S, et al.. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u20132159. DOI: 10.1056\/NEJMoa1612645"},{"key":"i2590-017X-9-3-113-b06","series-title":"JAMA Oncol","first-page":"1132","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","unstructured":"Vinayak S,Tolaney SM,Schwartzberg L, et al.. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132\u20131140. DOI: 10.1001\/jamaoncol.2019.1029"},{"key":"i2590-017X-9-3-113-b07","series-title":"Lancet Oncol","first-page":"1155","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","unstructured":"Domchek SM,Postel-Vinay S,Im SA, et al.. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 2020;21:1155\u20131164. DOI: 10.1016\/S1470-2045(20)30324-7"},{"key":"i2590-017X-9-3-113-b08","series-title":"JCM","first-page":"8854","article-title":"BRCA1 and 2 mutations and efficacy of pembrolizumab-based neoadjuvant chemotherapy in triple-negative breast cancer: a real-world multicenter analysis","volume":"14","author":"Fedele","year":"2025","unstructured":"Fedele P,Rizzo A,Landriscina M, et al.. BRCA1 and 2 mutations and efficacy of pembrolizumab-based neoadjuvant chemotherapy in triple-negative breast cancer: a real-world multicenter analysis. JCM. 2025;14:8854. DOI: 10.3390\/jcm14248854"},{"key":"i2590-017X-9-3-113-b09","series-title":"Lancet","first-page":"1453","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","unstructured":"von Elm E,Altman DG,Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20131457. DOI: 10.1016\/S0140-6736(07)61602-X"},{"key":"i2590-017X-9-3-113-b10","series-title":"JCO","first-page":"1346","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","unstructured":"Allison KH,Hammond MEH,Dowsett M, et al.. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. JCO. 2020;38:1346\u20131366. DOI: 10.1200\/JCO.19.02309"},{"key":"i2590-017X-9-3-113-b11","series-title":"J Clin Oncol","first-page":"2105","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP guideline update","volume":"36","author":"Wolff","year":"2018","unstructured":"Wolff AC,Hammond MEH,Allison KH, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2018;36:2105\u20132122. DOI: 10.1200\/JCO.2018.77.8738"},{"key":"i2590-017X-9-3-113-b12","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","unstructured":"Amin MB,Edge SB,Greene FL, et al.. eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017."},{"key":"i2590-017X-9-3-113-b13","series-title":"J Am Stat Assoc","first-page":"457","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","unstructured":"Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u2013481. DOI: 10.1080\/01621459.1958.10501452"},{"key":"i2590-017X-9-3-113-b14","series-title":"Cancer Chemother Rep","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163\u2013170."},{"key":"i2590-017X-9-3-113-b15","series-title":"J R Stat Soc Series B","first-page":"187","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Series B. 1972;34:187\u2013202. DOI: 10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"i2590-017X-9-3-113-b16","series-title":"JCO","first-page":"1796","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","unstructured":"von Minckwitz G,Untch M,Blohmer JU, et al.. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. JCO. 2012;30:1796\u20131804. DOI: 10.1200\/JCO.2011.38.8595"},{"key":"i2590-017X-9-3-113-b17","series-title":"JCO","first-page":"4414","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","unstructured":"Symmans WF,Peintinger F,Hatzis C, et al.. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. JCO. 2007;25:4414\u20134422. DOI: 10.1200\/JCO.2007.10.6823"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/3\/article-p113.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/3\/article-p113.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/3\/article-p113.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:42:41Z","timestamp":1784425361000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/3\/article-p113.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":17,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.36401\/jipo-26-11","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}